Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Curr Microbiol ; 76(4): 520-526, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30805700

RESUMO

Clostridium (Clostridioides) difficile ribotype 027 (RT027) was detected in Germany for the first time in 2007 during an outbreak in the region of Trier, Rhineland-Palatinate and is today the most prevalent ribotype (RT) in Europe. We aimed to determine the changes in RT distribution and corresponding antimicrobial resistance in clinical C. difficile isolates between two time points (2007 and 2017) in one tertiary care hospital in Germany. C. difficile isolates recovered in 2007 and in 2017 (80 isolates per year, respectively) from patients at a Tertiary Care University Hospital in North-Rhine Westphalia were analyzed. Isolates were characterized by ribotyping and susceptibility testing using gradient tests (metronidazole, vancomycin) and the disk diffusion method (moxifloxacin). Between 2007 and 2017, a clear switch from RT001 [18.75% (n = 15) in 2007 versus 3.75% (n = 3) in 2017 P = 0.003] to RT027 [0% in 2007 versus 21.25% (n = 17) in 2017] was evident. While minimal inhibitory concentrations (MICs) of vancomycin were stable, a significant metronidazole MIC creep was determined (MIC50 = 0.047 in 2007 versus MIC50 = 0.094 in 2017, P < 0.0001 using the Man-Whitney test). We detected one metronidazole-resistant isolate (0.6%). Interestingly, in total we encountered more isolates resistant to moxifloxacin in 2007 (42 (52.25%) than in 2017 [(30 (37.5%), P = 0.06)]). We could demonstrate that RT027 replaced RT001 in the last 10 years in our hospital. Furthermore, our data show a metronidazole MIC creep in C. difficile isolates over the last 10 years and an unexpected decrease of isolates resistant to moxifloxacin.


Assuntos
Antibacterianos/farmacologia , Clostridioides difficile/efeitos dos fármacos , Clostridioides difficile/genética , Infecções por Clostridium/microbiologia , Farmacorresistência Bacteriana , Ribotipagem/estatística & dados numéricos , Clostridioides difficile/classificação , Clostridioides difficile/isolamento & purificação , Infecções por Clostridium/epidemiologia , Monitoramento Epidemiológico , Fezes/microbiologia , Alemanha/epidemiologia , Humanos , Metronidazol/farmacologia , Testes de Sensibilidade Microbiana , Moxifloxacina/farmacologia , Ribotipagem/tendências , Centros de Atenção Terciária , Vancomicina/farmacologia
2.
Med Mal Infect ; 43(8): 322-30, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23876208

RESUMO

PCR targeting the gene encoding 16S ribosomal RNA (commonly named broad-range PCR or 16S PCR) has been used for 20 years as a polyvalent tool to study prokaryotes. Broad-range PCR was first used as a taxonomic tool, then in clinical microbiology. We will describe the use of broad-range PCR in clinical microbiology. The first application was identification of bacterial strains obtained by culture but whose phenotypic or proteomic identification remained difficult or impossible. This changed bacterial taxonomy and allowed discovering many new species. The second application of broad-range PCR in clinical microbiology is the detection of bacterial DNA from clinical samples; we will review the clinical settings in which the technique proved useful (such as endocarditis) and those in which it did not (such as characterization of bacteria in ascites, in cirrhotic patients). This technique allowed identifying the etiological agents for several diseases, such as Whipple disease. This review is a synthesis of data concerning the applications, assets, and drawbacks of broad-range PCR in clinical microbiology.


Assuntos
Bacteriologia/tendências , Reação em Cadeia da Polimerase/métodos , Ribotipagem/métodos , Bactérias/classificação , Bactérias/genética , Bactérias/isolamento & purificação , Infecções Bacterianas/diagnóstico , Infecções Bacterianas/microbiologia , DNA Bacteriano/genética , DNA Ribossômico/genética , Reações Falso-Positivas , Previsões , Humanos , Espectrometria de Massas , Reação em Cadeia da Polimerase/economia , Reação em Cadeia da Polimerase/tendências , RNA Bacteriano/genética , RNA Ribossômico 16S/genética , Ribotipagem/economia , Ribotipagem/tendências , Sensibilidade e Especificidade , Especificidade da Espécie
3.
Euro Surveill ; 14(15)2009 Apr 16.
Artigo em Inglês | MEDLINE | ID: mdl-19371514

RESUMO

Increasing rates of Clostridium difficile infection (CDI) with an unusual, severe course have been reported in several countries; this rise has partly been ascribed to the emergence of a virulent strain, C. difficile PCR ribotype 027 (CD027). An intriguing question is whether this could be related to increasing consumption of broadspectrum antibiotics. From 1997 to 2007, the number of hospital discharges in Denmark with the diagnosis enterocolitis caused by C. difficile increased from eight to 23 per 100,000 hospital discharges. This increase was proportional to a concomitant rise in the consumption of fluoroquinolones and cephalosporins. The first outbreak of CD027 in Denmark occurred from October 2006 to August 2007 and included 13 patients, most of them elderly, admitted to three hospitals in the same region. Most of the patients had overlapping periods of admission. All patients had been treated with broadspectrum antibiotics, in particular cephalosporins and fluoroquinolones, prior to positive culture of CD027. 30 days after confirmation of diagnosis, three of the 13 patients had died. Taken together, the data support the hypothesis that the increasing use of certain broadspectrum antibiotics may be related to a possible increase of C. difficile infection, and show that the specific contribution by CD027 in its emergence needs to be determined.


Assuntos
Cefalosporinas/efeitos adversos , Clostridioides difficile/genética , Fluoroquinolonas/efeitos adversos , Reação em Cadeia da Polimerase Via Transcriptase Reversa/tendências , Ribotipagem/tendências , Idoso , Idoso de 80 Anos ou mais , Cefalosporinas/administração & dosagem , Clostridioides difficile/efeitos dos fármacos , Dinamarca , Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos , Farmacorresistência Bacteriana Múltipla/genética , Enterocolite Pseudomembranosa/induzido quimicamente , Enterocolite Pseudomembranosa/genética , Feminino , Fluoroquinolonas/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos
4.
Syst Appl Microbiol ; 31(4): 258-68, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18922366

RESUMO

Thirty years have passed since Carl Woese proposed three primary domains of life based on the phylogenetic analysis of ribosomal RNA (rRNA) genes. Adopted by researchers worldwide, rRNA has become the "gold-standard" for molecular taxonomy, biodiversity analysis and the identification of microorganisms. The more than 700,000 rRNA sequences in public databases constitute an unprecedented hallmark of the richness of microbial biodiversity on earth. The International Workshop on Ribosomal RNA Technology convened on April 7-9, 2008 in Bremen, Germany (http://www.arb-silva.de/rrna-workshop) to summarize the current status of the field and strategize on the best ways of proceeding on both biological and technological fronts. In five sessions, 26 leading international speakers and approximately 120 participants representing diverse disciplines discussed new technological approaches to address three basic ecological questions: "Who is out there?" "How many are there?" and "What are they doing?".


Assuntos
Filogenia , RNA Ribossômico/genética , Ribotipagem/tendências , Análise de Sequência de RNA/tendências , Archaea/classificação , Archaea/genética , Bactérias/classificação , Bactérias/genética , Biologia Computacional/tendências , Bases de Dados de Ácidos Nucleicos/tendências , Microbiologia Ambiental , Genes de RNAr , RNA Arqueal/genética , RNA Bacteriano/genética , Software/tendências
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...